Document Type: Research Articles
Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Department of Infectious, Parasitic and Immune-Mediated Diseases, National Institute of Health, Viale Regina Elena 299, 00161 Rome, Italy.
Department of Stem Cells and Developmental Biology, Cell Science Research Centre, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
The effective discovery of clinically relevant tumor antigens holds a fundamental role for the development of
new diagnostic tools and anticancer immunotherapies. D393-CD20 mRNA is absent from normal resting B cells but
present in various malignant or transformed B cells. CD8+T lymphocytes play a central role in immunity to cancer.
In this study, we want use from T CD8+ against D393-CD20 for effect in RAMOS cell line. After isolation and
expanding of specific TCD8 + Lymphocyte against D393-CD20 antigen, for examining the effect of specialized T
lymphocyte clone of D393-CD20 antigen on RAMOS cell line, we co-cultured them together, and the rate of apoptosis
were examined by flow cytometry and cytotoxicity techniques by using MTT technique. We observed that specialized
TCD8+ lymphocyte of D393-CD20 antigen can induce apoptosis in malignant B-lymphocytes, and this antigen can
be a proper target for immunotherapy.